Company: TUTH
Filing Date: 2025-10-01
Form Type: 1-SA
Source: 0001683168-25-007356
Chunk: 10

Company: Standard Dental Labs Inc.
Filing Date: 2025-10-01
Form: 1-SA
Chunk 10
---
topic 470- 20) and Derivatives and Hedging – Contracts in Entity’s Own
Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The new guidance, among
other things, simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible
instruments, and amends existing earnings-per-share (“EPS”) guidance by requiring that an entity use the if converted method
when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for public business entities that meet the definition
of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after
December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal
years beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted the new guidance effective
from January 1, 2024.

| 8 |

ITEM 2. Other Information

None.

ITEM 3. Financial Statements

The accompanying semi-annual financial statements
have been prepared in accordance with the instructions to Form 1-SA. Therefore, they do not include all information and footnotes necessary
for a complete presentation of financial position, results of operations, cash flows, and stockholders’ equity in conformity with
U.S. GAAP. Except as disclosed herein, there has been no material change in the information disclosed in the notes to the financial statements
included in the Company’s annual financial statements for the year ended December 31, 2024 as included in the Company’s Form
1-A/A as filed with the Commission on July 17, 2025.

In the opinion of management, all adjustments
considered necessary for a fair presentation of the results of operations and financial position have been included, and all such adjustments
are of a normal recurring nature. Operating results for the six months ended June 30, 2025 are not necessarily indicative of the results
that can be expected for the year ending December 31, 2025.

| 9 |

<div align='center'>TABLE OF CONTENTS</div>

| Condensed Interim Consolidated Financial                                                                                          
 Statements                                                                                                                        
 Interim Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024                                                     
 Interim Consolidated Statements of Loss (Gain) and Comprehensive Loss for